Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9394 |
High Similarity |
NPD7808 |
Phase 3 |
0.9217 |
High Similarity |
NPD7251 |
Discontinued |
0.9157 |
High Similarity |
NPD6797 |
Phase 2 |
0.9096 |
High Similarity |
NPD7472 |
Approved |
0.9036 |
High Similarity |
NPD7054 |
Approved |
0.8944 |
High Similarity |
NPD3817 |
Phase 2 |
0.8935 |
High Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.8869 |
High Similarity |
NPD7074 |
Phase 3 |
0.881 |
High Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.8521 |
High Similarity |
NPD6166 |
Phase 2 |
0.8521 |
High Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8521 |
High Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.8421 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8383 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8313 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8284 |
Intermediate Similarity |
NPD5494 |
Approved |
0.8274 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.8253 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8225 |
Intermediate Similarity |
NPD919 |
Approved |
0.821 |
Intermediate Similarity |
NPD6799 |
Approved |
0.8171 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.8171 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.8155 |
Intermediate Similarity |
NPD5402 |
Approved |
0.8144 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.8107 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8095 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8095 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.8095 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8061 |
Intermediate Similarity |
NPD5403 |
Approved |
0.8049 |
Intermediate Similarity |
NPD5401 |
Approved |
0.8 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD2796 |
Approved |
0.8 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7923 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7917 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7879 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7862 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7853 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7831 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7829 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7821 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7816 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7811 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7765 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.774 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7735 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7735 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7733 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7684 |
Intermediate Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.7674 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7674 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.767 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.767 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7624 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7622 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7622 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7622 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7614 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7614 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7598 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7598 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7584 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7576 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7554 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7547 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7529 |
Intermediate Similarity |
NPD920 |
Approved |
0.7527 |
Intermediate Similarity |
NPD7240 |
Approved |
0.75 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7456 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7453 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7425 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7423 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7414 |
Intermediate Similarity |
NPD37 |
Approved |
0.7412 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7412 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7396 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7386 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7386 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7386 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7386 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7337 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.7337 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.7333 |
Intermediate Similarity |
NPD7697 |
Approved |
0.7333 |
Intermediate Similarity |
NPD7698 |
Approved |
0.7333 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.733 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7317 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7317 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7305 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7303 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7292 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.7286 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7286 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7247 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7208 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7208 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7208 |
Intermediate Similarity |
NPD8320 |
Phase 1 |
0.7208 |
Intermediate Similarity |
NPD8319 |
Approved |
0.7186 |
Intermediate Similarity |
NPD7701 |
Phase 2 |
0.7179 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7179 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7179 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7179 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7179 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7179 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7179 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7159 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7159 |
Intermediate Similarity |
NPD6386 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7143 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7136 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7135 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7118 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7107 |
Intermediate Similarity |
NPD5005 |
Approved |
0.7107 |
Intermediate Similarity |
NPD5006 |
Approved |
0.7077 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.7077 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7076 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7066 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7053 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.705 |
Intermediate Similarity |
NPD7583 |
Approved |
0.7045 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7041 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7041 |
Intermediate Similarity |
NPD8285 |
Discontinued |
0.7035 |
Intermediate Similarity |
NPD3887 |
Approved |
0.7033 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.703 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7015 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7011 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7011 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7011 |
Intermediate Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.7011 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7011 |
Intermediate Similarity |
NPD3146 |
Approved |
0.7006 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7006 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6995 |
Remote Similarity |
NPD7801 |
Approved |
0.699 |
Remote Similarity |
NPD4420 |
Approved |
0.6988 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6946 |
Remote Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.6946 |
Remote Similarity |
NPD1613 |
Approved |
0.6938 |
Remote Similarity |
NPD8155 |
Clinical (unspecified phase) |
0.6933 |
Remote Similarity |
NPD3266 |
Approved |
0.6933 |
Remote Similarity |
NPD3267 |
Approved |
0.6928 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6923 |
Remote Similarity |
NPD6535 |
Approved |
0.6923 |
Remote Similarity |
NPD6534 |
Approved |
0.6919 |
Remote Similarity |
NPD2403 |
Approved |
0.6919 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6919 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6915 |
Remote Similarity |
NPD5953 |
Discontinued |
0.6914 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6901 |
Remote Similarity |
NPD2346 |
Discontinued |
0.69 |
Remote Similarity |
NPD7680 |
Approved |
0.6898 |
Remote Similarity |
NPD7286 |
Phase 2 |
0.689 |
Remote Similarity |
NPD1019 |
Discontinued |
0.689 |
Remote Similarity |
NPD2798 |
Approved |
0.6882 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6882 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6869 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6854 |
Remote Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.685 |
Remote Similarity |
NPD6823 |
Phase 2 |
0.6845 |
Remote Similarity |
NPD943 |
Approved |
0.6845 |
Remote Similarity |
NPD4307 |
Phase 2 |
0.6842 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6833 |
Remote Similarity |
NPD6844 |
Discontinued |
0.6831 |
Remote Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.6829 |
Remote Similarity |
NPD1203 |
Approved |
0.6826 |
Remote Similarity |
NPD3268 |
Approved |
0.6826 |
Remote Similarity |
NPD1296 |
Phase 2 |
0.6824 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6821 |
Remote Similarity |
NPD6674 |
Discontinued |
0.6807 |
Remote Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.6805 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6805 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6802 |
Remote Similarity |
NPD2353 |
Approved |
0.6802 |
Remote Similarity |
NPD2355 |
Clinical (unspecified phase) |
0.6792 |
Remote Similarity |
NPD5619 |
Clinical (unspecified phase) |
0.6782 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.678 |
Remote Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.6778 |
Remote Similarity |
NPD5889 |
Approved |
0.6778 |
Remote Similarity |
NPD5890 |
Approved |
0.6778 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.677 |
Remote Similarity |
NPD17 |
Approved |
0.6768 |
Remote Similarity |
NPD3225 |
Approved |
0.6766 |
Remote Similarity |
NPD3027 |
Phase 3 |
0.6755 |
Remote Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.6748 |
Remote Similarity |
NPD9717 |
Approved |
0.6747 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6747
|
Remote Similarity |
NPD1530 |
Clinical (unspecified phase) |